Silence and Replace Gene Therapy Cleared for Oculopharyngeal Muscular Dystrophy Clinical Trial
Benitec Biopharma is planning to initiate a phase 1b/2a clinical trial to evaluate BB-301.
Benitec Biopharma has received FDA clearance for its investigational new drug (IND) application for BB-301, an investigational adeno-associated virus (AAV) vector-based silence and replace gene therapy intended to treat oculopharyngeal muscular dystrophy (OPMD)-related dysphagia.1
BB-301 is based on the company’s DNA-directed RNA interference (ddRNAi) platform and consists of a bifunctional construct that expresses a codon-optimized copy of the Poly-A Binding Protein Nuclear-1 gene (PABPN1) and 2 small inhibitory
“The FDA’s clearance of our IND for BB-301 is a significant milestone for OPMD patients and for Benitec as a company,” Jerel A. Banks, MD, PhD, the executive chairman and CEO of Benitec Biopharma, said in a statement.1 “The clearance of BB-301 for clinical use represents the first potential treatment for these frequently debilitating and possibly fatal symptoms of OPMD.”
Approximately 15,000 people in the United States, Canada, Western Europe, and Israel have OPMD. Symptoms of the disorder include inability to swallow liquids and solids, chronic malnutrition, chronic choking, regurgitation, aspiration, eyelid drooping, proximal limb weakness, and potentially fatal aspiration pneumonia.1,2 Currently, the standard of care for OPMD consists of palliative treatment; there are no disease-modifying therapies available. In addition to the potential benefits of providing a functional copy of PABPN1, Benitec Biopharma expects that BB-301 will improve atrophy and muscle weakness by reducing the build-up of insoluble mutant PABPN1.
In addition to the United States, Benitec Biopharma also intends to evaluate BB-301 at clinical trial sites in Canada and France.3 In a May 15, 2023, operational update the company stated that it had submitted a natural history study trial package to Canada’s Research Ethics Board. It also anticipates clearance of a clinical trial application (CTA) for the phase 1b/2a clinical trial in Canada in the second half of 2023. Benitec Biopharma additionally noted that it expects to complete filing of a CTA for the clinical trial in France in the third quarter of 2023.
“We remain focused on opening additional clinical study sites in Canada and France, pending ongoing discussions with Institutional Review Boards and regional regulators,” Banks said in the operational update.3
Substantial progress in the realm of gene therapy for muscular dystrophy was recently made with the FDA’s
REFERENCES
1. Benitec Biopharma receives FDA clearance of the IND for BB-301 for the treatment of oculopharyngeal muscular dystrophy. News release. Benitec Biopharma Inc. June 26, 2023. Accessed June 28, 2023. https://ir.benitec.com/news-events/press-releases/detail/102/benitec-biopharma-receives-fda-clearance-of-the-ind-for
2. Areas of Research. Benitec Biopharma Inc. Website. Accessed June 28, 2023. https://benitec.com/our-programs/areas-of-research/
3. Benitec Biopharma releases third quarter 2023 financial results and provides operational update. News release. Benitec Biopharma Inc. May 15, 2023. Accessed June 28, 2023. https://ir.benitec.com/news-events/press-releases/detail/101/benitec-biopharma-releases-third-quarter-2023-financial
4. Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy. News release. Sarepta Therapeutics. June 22, 2023. Accessed June 28, 2023. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-elevidys-first-gene?_ga=2.14016759.1120318671.1687966860-1064823149.1687449584
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025